Skip to main content

Table 1 Patient characteristics and clinicopathologic features. (n = 40)

From: Antineoplastic treatment effect on bone mineral density in Mexican breast cancer patients

  Premenopausal (n = 19) Postmenopausal (n = 21)
Age (mean) 43 53.55
Basal BMI (kg/m2, mean) 28.04 31.68
Clinical stage
 I 3 2
 IIA 5 7
 IIB 3 5
 IIIA 5 4
 IIIB 3 3
Histological subtype
 Invasive ductal carcinoma 18 19
 Invasive lobulillar carcinoma 1 2
Treatment
 Neoadyuvant 9 9
 Adyuvant 10 12
Molecular subtypes (n = 28)a
 Luminal A (RE+, RP+/-, HER2neu-) 1 3
 Luminal B (RE+, RP+/-, HER2neu+) 4 5
 HER2 (RE-, RP+/-, HER2+) 5 2
 Triple negative (RE-, RP-, HER2-) 5 3
Chemotherapy schemeb
 -FAC (5-Fluorouracile, Adriamicin, Cyclophosphamide) 15 17
 -FEC (5-Fluorouracile, Epirrubicin, Cyclophosphamide) - 1
 -FAC + P(5-Fluorouracile, Adriamicin, Cyclophosphamide + Paclitaxel) 3 1
 -FA (5-Fluorouracile, Cyclophosphamide) 1 -
 -DAC (Docetaxel, Adriamicin, Cyclophosphamide) - 2
  1. Data in table are number of cases
  2. aBecause patient recruitment started in 2007 and immunohistochemistry determination of hormone receptors was instituted as part of the routine battery of tests in 2008, not all underwent such a test
  3. bNational Comprehensive Cancer Network (NCCN) Clinical guidelines